New Genomic Atlas Reveals Hidden Genes Driving Type 2 Diabetes
Recent research from The Jackson Laboratory (JAX) has uncovered dozens of unexpected genes strongly linked to type 2 diabetes (T2D). Published in The EMBO Journal, the study presents a highly detailed genomic atlas of pancreatic cells, pointing to new therapeutic strategies centered around cell death and vitamin A metabolism.
"This is a huge problem. Almost everyone knows someone affected by diabetes," explains JAX Professor Michael L. Stitzel, who directed the study. "Identifying the genes that contribute to disease is exciting because it gives us actionable information for precision medicine."
Unlocking the Pancreas at a Cellular Level
The research team analyzed nearly 250,000 pancreatic islet cells from 48 human donors across non-diabetic, prediabetic, and diabetic profiles. These islet clusters contain the vital cells responsible for producing insulin, the hormone that regulates blood glucose levels.
By categorizing 14 distinct cell types, researchers observed how genetic expression changes—like turning down the volume on a stereo rather than hitting the power button—as diabetes progresses:
Significant Beta Cell Loss: T2D patients lose approximately 25% of their beta cells, which are the primary insulin producers.
Cellular Aging: The study confirmed that a subgroup of the remaining beta cells enters a "senescent" state, becoming aged and less functional.
A Beta-Specific Impact: Surprisingly, the changes driving T2D appeared highly specific to beta cells, rather than resulting from cascading effects from other pancreatic cell types like alpha or delta cells.
The Gene Hunt: Narrowing Down the Suspects
By combining observational data with genome-wide association studies, the team initially identified 511 genes with altered activity in T2D beta cells. Using genetic, protein, and metabolic analyses in mouse models, they narrowed this list down to 58 genes that likely play a direct, causal role in the beta cell defects and cell death associated with T2D.
Overlooked Therapeutic Targets
The study highlighted specific genes and metabolic pathways previously underappreciated in diabetes research:
The GRAMD2B and PDZK1 Genes: Both genes appear crucial for maintaining beta cell mass. GRAMD2B levels were consistently lower in T2D, and deleting it in mice led to significant glucose management issues. While deleting PDZK1 in mice didn't disrupt glucose management directly, reducing it in human islets actively increased cell death.
Vitamin A Metabolism: Beta cells in T2D patients showed reduced activity in genes responsible for converting dietary vitamin A into retinoic acid. Because retinoic acid helps beta cells survive stress, this reduction makes the cells increasingly fragile and prone to early death.
"This vitamin A pathway had been loosely linked to diabetes before, but this is the first time we've been able to clearly show at the gene level that it is systematically changing in type 2 diabetes," noted Khushdeep Bandesh, a staff scientist who co-led the study.
An Open Resource for Future Therapies
While careful clinical studies are still needed to determine if interventions like vitamin A supplementation could effectively preserve pancreatic function, this research provides the most detailed view yet of the molecular drivers behind a disease affecting over 500 million people globally.
Rather than keeping their findings closed, the JAX team has made their entire dataset available to the global scientific community. Researchers across multiple countries are already using the open-source atlas to study how these different pancreatic cell types communicate, helping to accelerate the global push for new, targeted diabetes treatments.
Source: Medical Xpress | April 16, 2026